Recently, Kanemura et al. reported an ORR of 53.8%, a DCR of 84.6%, and mPFS 6.1 months in 13 pretreated HER2 MUT NSCLC patients treated with mobocertinib and TDM1, including those who had developed resistance to T-DXd [75]. Here, ERBB2 is linked to non-small cell lung carcinoma.